Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors Journal Article

   

Authors:	Bewersdorf, J. P.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; Stone, R. M.; Aldoss, I.; Ball, B. J.; Stahl, M.
Article Title:	Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
Abstract:	FLT3, IDH1 and IDH2 inhibitors as well as venetoclax in combination with hypomethylating agents or low-dose cytarabine have expanded treatment options for patients with acute myeloid leukemia (AML). However, little data exist on the efficacy of venetoclax-based therapies in AML patients previously treated with FLT3 or IDH1/2 inhibitors. In this multicenter, retrospective cohort study, we included 44 patients who received venetoclax-based therapy after FLT3, IDH1 or IDH2 inhibitors. The overall response rate (ORR; composite of complete remission [CR]/CR with incomplete count recovery, partial remission, and morphologic leukemia free state) was 56.8% (18.2% CR) and a median overall survival of 9.2 months. While 6 out of 7 patients with IDH1 mutations who had previously been treated with ivosidenib responded to venetoclax-based therapy, FLT3-ITD mutations were associated with a lower response rate. Our data suggest that venetoclax can be an effective salvage therapy in patients previously treated with IDH1/2 or FLT3 inhibitors. © 2022 Informa UK Limited, trading as Taylor & Francis Group.
Keywords:	adult; clinical article; aged; retrospective studies; gene mutation; overall survival; genetics; leukemia, myeloid, acute; clinical trial; salvage therapy; sorafenib; cancer combination chemotherapy; cytarabine; low drug dose; cohort analysis; retrospective study; cancer resistance; survival time; cancer specific survival; multicenter study; leukemia relapse; fused heterocyclic rings; outcomes; targeted agents; azacitidine; leukemia remission; isocitrate dehydrogenase; aml; isocitrate dehydrogenase 1; cd135 antigen; midostaurin; acute myeloid leukemia; overall response rate; fms-like tyrosine kinase 3; decitabine; quizartinib; idh1 protein, human; humans; human; male; female; article; venetoclax; crenolanib; gilteritinib; flt3 protein, human; enasidenib; bridged bicyclo compounds, heterocyclic; ivosidenib; cedazuridine plus decitabine
Journal Title:	Leukemia and Lymphoma
Volume:	64
Issue:	1
ISSN:	1042-8194
Publisher:	Taylor & Francis Group
Date Published:	2023-01-01
Start Page:	188
End Page:	196
Language:	English
DOI:	10.1080/10428194.2022.2136952
PUBMED:	36287540
PROVIDER:	scopus
PMCID:	PMC9905301
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85141085026&doi=10.1080%2f10428194.2022.2136952&partnerID=40&md5=ff899fdbf48fb7d925aa96741182f146
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/203451